Document Detail


Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer's disease.
MedLine Citation:
PMID:  20859244     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
OBJECTIVE: Cytochrome P450 (CYP) 2D6 enzyme is the major responsible for the metabolism of donepezil, an inhibitor of acetyl cholinesterase currently used for the symptomatic treatment of mild-to-moderate Alzheimer's disease (AD). Functional polymorphisms in the CYP2D6 gene may affect enzyme activity and thus, the metabolism of donepezil. The aim of this study was to evaluate the effect of 16 functional polymorphisms in the CYP2D6 gene on the clinical response to donepezil treatment in patients with mild-to-moderate AD.
METHODS: In this multicenter prospective cohort study we evaluated 57 unrelated Caucasians clinically diagnosed as AD according to the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association Work Group criteria. Patients were treated with donepezil (5-10 mg/daily) for 6 months. The response to donepezil treatment was evaluated at 6-month follow-up according to the National Institute for Health and Clinical Excellence requirements. The identification of 16 clinically relevant CYP2D6 gene variants was performed by a high-throughput genetic analysis.
RESULTS: Thirty-eight of 57 patients (67%) were responders and 19 patients (33%) were nonresponders to donepezil treatment. A significantly higher frequency of gene variants conferring decreased or absent enzyme activity was observed in responder than in nonresponder patients (73.68% vs. 36.84%; P=0.005). The presence of gene variants conferring decreased or absent activity of the CYP2D6 enzyme was significantly associated with a clinical response to donepezil treatment (odds ratio=6.286; 95% confidence interval=1.828-21.667).
CONCLUSIONS: Functional polymorphisms in the CYP2D6 gene can influence the clinical efficacy of donepezil. The analysis of CYP2D6 genotypes may be useful in identifying subgroups of AD patients with different clinical response to donepezil treatment.
Authors:
Davide Seripa; Alessandra Bizzarro; Andrea Pilotto; Grazia D'onofrio; Gennaro Vecchione; Antonietta P Gallo; Leandro Cascavilla; Francesco Paris; Elvira Grandone; Patrizia Mecocci; Stefano A Santini; Carlo Masullo; Alberto Pilotto
Related Documents :
20599474 - Cerebrospinal fluid profile of amyloid β42 (aβ42), htau and ubiquitin in north indian...
16298234 - Elevated levels of neural recognition molecule l1 in the cerebrospinal fluid of patient...
17997624 - The effect of background stimulative music on behavior in alzheimer's patients.
11092534 - Short telomeres in patients with vascular dementia: an indicator of low antioxidative c...
456054 - Vectorcardiographic detection of early hemodynamic abnormalities in chronic obstructive...
7062444 - Urinary excretion of urate in renal calcium stone disease and in renal tubular acidific...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Pharmacogenetics and genomics     Volume:  21     ISSN:  1744-6880     ISO Abbreviation:  Pharmacogenet. Genomics     Publication Date:  2011 Apr 
Date Detail:
Created Date:  2011-03-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101231005     Medline TA:  Pharmacogenet Genomics     Country:  United States    
Other Details:
Languages:  eng     Pagination:  225-30     Citation Subset:  IM    
Affiliation:
Geriatric Unit & Gerontology-Geriatrics Research Laboratory, Department of Medical Sciences, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo (FG), Italy. dseripa@operapadrepio.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action...
Next Document:  Glutamatergic gene variants impact the clinical profile of efficacy and side effects of haloperidol.